GOSS · Gossamer Bio, Inc.

📣 What GOSS Says Is Next

• this year · “The FDA will determine whether to accept the NDA for filing following its initial review of the application, which the Company anticipates could occur later this year.”
  Company press release, Sep 23, 2026 · SEC filing
• in 2026 · “If the NDA Acceptance Milestone occurs in 2026, the Company expects to receive the full $150 million of committed capital in 2026.”
  Company press release, Aug 21, 2026 · SEC filing
• this year · “Subject to the outcomes of that meeting, we expect to submit an NDA for seralutinib in PAH in September of this year.”
  Company press release, May 18, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Dec 2026 · Phase 3 · Recruiting · Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
  Registry primary completion date, not a results date
• Dec 2027 · Phase 2 · Active Trial · Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not GOSS's own candidates): Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GOSS holds $57M in cash and short-term investments (as of Jun 30, 2026) and burns about $39.1M/quarter from operations, an estimated runway of 4.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

• Cash runway 4 months +40
• Shelf registration (S-3ASR, Jan 2026) +10
• Going-concern doubt in the latest 10-Q +15Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. 10-Q, Aug 2026
• Share count +115% in a year +20
• Raised after last reported balance sheet (Aug 2026) -10

Recent financing filings on SEC EDGAR:

• Aug 21, 2026 · Private placement (8-K Item 3.02) · 8-K
• Jun 5, 2026 · Private placement (8-K Item 3.02) · 8-K
• Jan 28, 2026 · Shelf registration · S-3ASR
• Sep 25, 2025 · Private placement (8-K Item 3.02) · 8-K
• May 6, 2024 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GOSS files for a raise →

👥 Who Owns GOSS

Share count 488,846,722 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.